GLP-1 receptor agonist exposure shows no link to major adverse pregnancy outcomes
New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health shows that, following a review and meta-analysis of available studies, use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) drugs for diabetes and weight management in women…
Read original article on The Medical News →Related news
-
Novel surgical technique restores clitoral sensation using buccal mucosa graft
United Kingdom
-
Real-world data reveals higher reported GLP-1 side effects in female patients
United Kingdom
-
Study examines driving cessation in dementia and MCI
United Kingdom
-
Early-onset type 2 diabetes trial demonstrates significant 24-week fat loss
United Kingdom
-
Children with a common genetic variant may have more inflammation in response to an asthma drug
United Kingdom
-
Egg prices have tumbled since Trump returned to office. Here's why
United States
-
Trade tensions mean fewer Canadians flocking to South Florida
United States
-
Why good leaders listen
United Kingdom